Cellularly active N-hydroxyurea FEN1 inhibitors block substrate entry to the active site by Exell, JC et al.
This is an author produced version of Cellularly active N-hydroxyurea FEN1 inhibitors 
block substrate entry to the active site.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/118189/
Article:
Exell, JC, Thompson, MJ, Finger, LD et al. (11 more authors) (2016) Cellularly active 
N-hydroxyurea FEN1 inhibitors block substrate entry to the active site. Nature Chemical 
Biology, 12 (10). pp. 815-821. ISSN 1552-4450 
https://doi.org/10.1038/nchembio.2148
© 2016 Nature America, Inc. This is an author produced version of a paper published in 
Nature Chemical Biology. Uploaded in accordance with the publisher's self-archiving 
policy.
promoting access to
White Rose research papers
eprints@whiterose.ac.uk
http://eprints.whiterose.ac.uk/
Cellular Active N-Hydroxyurea FEN1 Inhibitors Block Substrate 
Entry to the Active Site
Jack C. Exell1,6, Mark J. Thompson1, L. David Finger1, Steven J. Shaw1, Judit Debreczeni2, 
Thomas A. Ward4, Claire McWhirter2, Catrine L. B. Siöberg5, Daniel Martinez Molina5, W. 
Mark Abbott2, Clifford D. Jones3, J. Willem M. Nissink3,*, Stephen T. Durant4,*, and Jane A. 
Grasby1,*
1Centre for Chemical Biology, Department of Chemistry, Krebs Institute, University of Sheffield, 
Sheffield, S3 7HF, UK
2Discovery Sciences, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, 
Unit 310 (Darwin Building), Cambridge Science Park, Milton Road, Cambridge, CB4 0WG, UK
3Chemistry, Oncology, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, 
Unit 310 (Darwin Building), Cambridge Science Park, Milton Road, Cambridge, CB4 0WG, UK 
and Alderley Park, Cheshire, SK10 4TG, UK
4Bioscience, Oncology, Innovative Medicines and Early Development Biotech Unit, CRUK 
Cambridge Institute, Robinson Way, Cambridge, CB2 0RE, UK; Alderley Park, Cheshire, SK10 
4TG, UK and AstraZeneca, Unit 310 (Darwin Building), Cambridge Science Park, Milton Road, 
Cambridge, CB4 0WG, UK
5Pelago Bioscience AB, Nobels Väg 3, 17165, Sweden
Abstract
The structure-specific nuclease human flap endonuclease-1 (hFEN1) plays a key role in DNA 
replication and repair and may be of interest as an oncology target. We present the first crystal 
structure of inhibitor-bound hFEN1 and show a cyclic N-hydroxyurea bound in the active site 
coordinated to two magnesium ions. Three such compounds had similar IC50 values but differed 
subtly in mode of action. One had comparable affinity for protein and protein–substrate complex 
and prevented reaction by binding to active site catalytic metal ions, blocking the unpairing of 
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substrate DNA necessary for reaction. Other compounds were more competitive with substrate. 
Cellular thermal shift data showed engagement of both inhibitor types with hFEN1 in cells with 
activation of the DNA damage response evident upon treatment. However, cellular EC50s were 
significantly higher than in vitro inhibition constants and the implications of this for exploitation 
of hFEN1 as a drug target are discussed.
Introduction
Flap endonuclease 1 (FEN1) is the prototypical member of the 5ᓉnuclease superfamily,1,2 
whose activities span a range of cellular pathways involved in DNA replication and genome 
maintenance.3,4 FEN1 is a structure-selective metallonuclease essential for Okazaki 
fragment maturation through efficient removal of 5ᓉ-flaps resulting from strand 
displacement during lagging-strand synthesis.5,6 This reaction produces nicked DNA 
suitable for ligation, thereby ensuring maintenance of genomic fidelity. FEN1 is also 
involved in long-patch base excision repair7–9 (LP-BER), amongst other pathways.
Given its critical replicative function, it is not surprising that FEN1 overexpression is 
characterized in multiple cancer types10–13 such that it has been suggested as both a 
biomarker relating to prognosis and disease progression, and a potential therapeutic target. 
Target validation studies have focused either on chemosensitization14,15 or synthetic lethal 
interactions16–19 with established oncogenes. Synthetic lethality arises when loss of 
function of either gene of an interacting pair is not cytotoxic, but mutation or inhibition of 
both does cause cell death; hence, targeting interacting partners of mutated genes in cancer 
offers potential for selective killing of cancer cells.
Therapeutic interest in FEN1 arises from its known synthetic lethal interactions with several 
genes frequently mutated in cancers.16,17,20 FEN1 inhibition selectively impairs 
proliferation of colon cancer cells deficient in Cdc4 and Mre11a,16,18 both frequently 
mutated in colorectal cancers. FEN1 has also emerged as a potential chemosensitizing target 
due to its role in LP-BER17 since it is critical for repair of MMS (methyl 
methanesulfonate)-induced alkylation damage,21 and its knockdown or inhibition increases 
sensitivity to TMZ (temozolomide) in glioblastoma13 and colorectal cancer14,16,18 cell 
lines.
This considerable interest in human FEN1 (hFEN1) as a drug target has prompted 
development of high-throughput screening procedures22,23 and the discovery of an N-
hydroxyurea based series of hFEN1 inhibitors.24 We investigated the specificity and mode 
of action of these compounds and found they prevented access of the scissile phosphate 
diester of substrate DNA to catalytic metal ions. We also demonstrated cellular activity and 
target engagement in live cells, leading to activation of the DNA damage response and 
apoptosis.
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Results
N-Hydroxyurea hFEN1 inhibitors bind catalytic site metals
Inhibitor 124 (Figure 1a) was co-crystallized with hFEN1–Mg2+ truncated after residue 336 
(hFEN1-336Δ), which retains all catalytic features but lacks the flexible 44 amino acid C-
terminus.25,26 The crystal structure of the hFEN1-336Δ–inhibitor complex (Figure 1b) was 
solved at 2.84 Å resolution (Supplementary Results, Supplementary Table 1 and 
Supplementary Figure 1; PDB ID 5FV7) and resembled a kidney bean with the active site 
and requisite divalent metal ions residing at the indentation. The structure in the presence of 
the active site-bound inhibitor closely resembled that of hFEN1 in complex with 
proliferating cell nuclear antigen (PCNA).27 As with the PCNA-bound structure, no density 
was observed for the helical arch ( ?4 and  ?5) and  ?2- ?3 loop regions, which are visible 
when co-crystallized with substrate or product DNA.2
The inhibitor was situated in the protein’ s nuclease active site with the N-hydroxyurea 
moiety directly coordinating two Mg2+ ions positioned 4.5 Å apart (Figure 1b), anchored by 
inner-sphere metal-coordinating contacts from carboxylates of E160, D179 and D181 and 
outer-sphere or water-mediated contacts from D34, D86, E158 and D233 (Figure 1c). The 
thiophene ring of the inhibitor filled a small hydrophobic pocket formed by M37, Y40 and 
V133, and the sulfur of M37 exhibited a short-distance (4Å) favorable contact to the electron 
deficient pyrimidine-2,4-dione ring of the ligand. The 2,3-dihydrobenzo[b][1,4]dioxine 
sidechain contacted M37 and Y40, though these contacts were less directional and mostly 
hydrophobic in nature. It was evident that different binding poses in the active site are 
possible for the N-hydroxyurea series of inhibitors, which goes some way to rationalizing 
the reported SAR.24 The relatively weak nature of protein contacts with the sidechain (N1-
substituent) explained the modest improvement in IC50 values seen for compounds modified 
at this position.24 It is also understandable how substitutions restricting the conformational 
freedom of the sidechain—for example, introduction of a methyl group at the 7-position of 
the thieno[3,2-d]pyrimidine-2,4-dione system of 1—would significantly reduce binding 
affinity and therefore increase IC50, as is reported.24
Inhibitor binding pose suggests a possible mode-of-action
Coordination of 1 to the metal ions that catalyze specific phosphodiester hydrolysis of the 
substrate suggested a mode of action for this inhibitor. We modelled ternary protein–
inhibitor–DNA complexes using the present hFEN1-336Δ–inhibitor structure together with 
the published hFEN1-336Δ–product DNA complex2 (Figure 1d). Alignment of product-
bound and ligand-bound structures indicated that the inhibitor and the phosphate monoester 
of the product DNA strand both co-locate to bind the metal ions. Conversely, in the 
hFEN1-336Δ–substrate DNA complex2, the scissile bond is not in contact with active site 
metal ions because the DNA is base-paired. It is assumed a pre-reactive complex forms 
initially that requires the end of the DNA duplex to unpair and bind to metal ions as a 
prerequisite for cleavage.1,2,28 Hence, it was considered plausible that substrate could bind 
in the presence of inhibitor, but that this prevents DNA from accessing the catalytic metals 
as required for hydrolysis to occur (Figure 2a). An alternative hypothesis was that the 
inhibitor precludes DNA binding, although the compound was bound far from the other two 
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main areas of protein–DNA interaction (K+/H2TH motif and 3ᓉ-flap binding pocket). We 
undertook further work to characterize the hFEN1-inhibitor interaction and establish 
whether the N-hydroxyurea inhibitors compete with substrate DNA binding.
Inhibitor binding to hFEN1 requires magnesium ions
We quantified the interaction of 1, and related analogs 2 and 322 bearing a smaller or no 
sidechain (Figure 1a), with the substrate-free protein using isothermal titration calorimetry 
(ITC; Supplementary Table 2). Similar dissociation constants (KD) were obtained for 1 and 
2 in the presence of Mg2+ with either hFEN1-336Δ (Supplementary Figure 2) or full-length 
hFEN1 (Supplementary Figure 3a,b) but the KD of 3 was approximately 10-fold higher, 
suggesting interactions between the sidechains of 1 and 2 and the protein contribute to 
binding.
Ca2+ ions are often employed as a nonviable cofactor in biophysical measurements with 
hFEN1 because they facilitate accommodation of the substrate DNA and its required 
conformational changes,28,29 but do not support catalysis. In fact, Ca2+ ions are a 
competitive inhibitor of 5ᓉ-nuclease reactions with respect to Mg2+,30,31 implying both ions 
occupy similar sites on the protein. However, KD values were drastically increased on 
replacement of Mg2+ with Ca2+ (Supplementary Figure 4), showing the latter did not 
support inhibitor binding. Thus, in accord with the crystal structure, interaction of 1 and 2 
with hFEN1 was specific to the nuclease core domain and required Mg2+. To provide an 
estimate of residence time, we probed the interaction of 1 with hFEN1-336Δ using surface 
plasmon resonance (Supplementary Figure 2d) and obtained a dissociation constant similar 
to ITC with a residence time of 3 min.
Inhibitors bind to both protein and protein–DNA complex
Kinetic experiments were used to characterize hFEN1 inhibition by 1, 2 and 4. We measured 
rates of hFEN1-336Δ-catalyzed reaction with an optimal endonucleolytic double-flap 
substrate bearing a 5ᓉ-fluorescein label32 (DF1; Figure 2a, and Supplementary Figure 5a). 
At substrate concentration close to KM (100 nM), IC50 values for all three compounds were 
similar (Table 1), and a related exonucleolytic substrate gave similar IC50 results 
(Supplementary Figure 6a,b). Mode of inhibition was determined by globally fitting rates of 
reaction at varying inhibitor and double-flap substrate concentrations to four inhibition 
models: competitive, uncompetitive, non-competitive and mixed inhibition (Equations 2–5, 
online methods).
The uncompetitive model—where the inhibitor can only bind to enzyme–substrate complex
—afforded a poor fit for 1, which was unsurprising given the compound’ s high affinity for 
free protein. The competitive model, where binding of inhibitor and substrate are mutually 
exclusive, also proved unsuitable but the mixed and non-competitive models produced 
acceptable fits (Figure 2b-d and Supplementary Figure 7). These models both assume the 
inhibitor can bind to DNA-free and DNA-bound forms of the enzyme, but the non-
competitive model (Equation 4) assumes both complexes have equivalent ligand dissociation 
constants. Allowing dissociation constants to vary (mixed inhibition; Figure 2b and Equation 
5) produced a marginally better data fit, yielding near-equivalent dissociation constants for 
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1(Table 1). Statistical model selection using Aikake’ s Information Criteria (AIC) 
overwhelmingly preferred the mixed inhibition model.
With compound 2, only the competitive (Equation 3) and mixed inhibition models produced 
acceptable fits (Figure 2e, Supplementary Figure 8). The same statistical criteria (AIC) again 
favored the mixed model, but in this case the derived dissociation constants (Kic and Kiu) 
varied by an order of magnitude (Table 1). For compound 4, only the competitive model 
produced an acceptable fit (Figure 2f, Table 1 and Supplementary Figure 9). Thus, whereas 
1, 2 and 4 all bound to hFEN1–Mg2+ with similar efficiency, only 1 showed notable affinity 
for the enzyme-substrate complex (hFEN1–Mg2+–DNA), binding both DNA-free and DNA-
bound forms of the enzyme with comparable dissociation constants.
Evidence for an hFEN1–Mg2+–Inhibitor–DNA complex
To verify formation of a quaternary complex of enzyme–Mg2+–inhibitor–DNA (E–Mg2+–I–
DNA), we tested the ability of E–Mg2+–I to form complexes with DNA without significant 
hydrolysis of the substrate occurring. High concentrations of 1 or 2 (100 µM) slowed the rate 
of Mg2+-catalyzed reaction 10,000-fold under single-turnover conditions (Table 1 and 
Supplementary Figure 10), but appreciable substrate cleavage was still seen over the 
timescale required for biophysical measurements. Because Ca2+ did not support inhibitor 
binding (Supplementary Figure 4), substituting it in place of Mg2+ as a nonviable cofactor 
was not applicable. Instead, we employed a previously characterized hFEN1 mutant, R100A. 
Arg100 is strictly conserved in FEN1 proteins and its mutation to alanine slows reaction 
7,000-fold.33 The half-life of substrate with R100A–Mg2+ and inhibitors was sufficiently 
long to permit measurements without significant product formation (Supplementary Figure 
11), and ITC confirmed the mutation did not affect inhibitor binding (Supplementary Table 
2).
Both 1 and 2 formed R100A–Mg2+–I–DNA complexes as demonstrated by increases in 
anisotropy (r) of DF1 substrate upon titration with R100A–Mg2+–I, with r reaching a 
common limiting value at high enzyme concentration (Figure 3a). Data fitting to a simple 
binding isotherm revealed similar trends in KD between R100A and its wt equivalent, with 
which the use of non-catalytic Ca2+ ions was necessary to prevent reaction (Supplementary 
Figures 11a, 12a–d). Competing away bound, FAM-labeled substrate with its unlabeled 
equivalent demonstrated specific interaction between R100A and this substrate 
(Supplementary Figures 5a,b, 12h). Substrate dissociation constants differed between 
quaternary complexes containing 1 or 2 (Figure 3a): with compound 1, R100A–Mg2+–1 
displayed a KD only threefold greater than that for R100A–Ca2+. In contrast, the substrate 
bound 10-fold more weakly to R100A–Mg2+–2. These results were consistent with 1 having 
a closer Kiu value relative to Kic than 2, again suggesting 2 was more competitive than 
mixed in character.
DNA is bent in complexes with or without inhibitors
hFEN1 possesses two juxtaposed double-stranded DNA binding sites that accommodate 
double-flap substrate DNA in a conformation with a 100° bend at the junction. To ascertain 
whether DNA bound similarly in the presence of inhibitor, we examined substrate bending 
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using FRET. We labelled double-flap substrate with a rhodamine-fluorescein dye pair on its 
respective duplexes, and verified binding to hFEN1 produces an increase in FRET signal34 
(Figure 3b and Supplementary Figures 5c-f, 13, 14). Titration of R100A–Ca2+ or R100A–
Mg2+–1 into the labeled substrate produced comparable FRET efficiency start and end 
values (Figure 3b) confirming the enzyme had engaged both DNA binding sites with or 
without inhibitor. The substrate KD was raised by a factor of three in the presence of 1, 
whereas substrate binding was much weaker with 2 present (Figure 3b and Supplementary 
Table 3); hence, these results mirrored those obtained earlier by fluorescence anisotropy.
Inhibitors bound to catalytic metals block DNA unpairing
Unpairing of the reacting substrate duplex, which places the target phosphodiester onto 
active site metal ions, is a prerequisite for hFEN1-catalysed reaction one nucleotide into the 
double-stranded DNA (Figure 2a).28 This metal ion-dependent conformational change may 
be monitored using substrates containing a tandem 2-aminopurine (2AP) exciton pair at the 
–1 and –2 positions of the 5ᓉ-flap strand (DF3, Supplementary Figure 5g) by measuring 
changes in the low energy exciton-coupled CD spectrum resulting from the 2APs, usually in 
the presence of Ca2+ to prevent reaction.28
In adopting the reactive conformation, the +1 and −1 nucleotides are assumed to become 
extrahelical whereas the −2 nucleotide remains base-paired. In the absence of active site 
divalent ions (EDTA added), a strong maximum at 330 nm is observed from the R100A–
DNA complex, due to the exciton pair and consistent with substrate remaining base-paired.
28 With R100A–Ca2+–DNA, the DNA conformational change reverses the sign of the CD 
signal producing a deep minimum at 310 nm (Figure 4a). In the presence of 1 or 2, the 
measured CD signal of R100A–Mg2+–I–DNA did not differ significantly from that observed 
for R100A–DNA without divalent ions (Figure 4b,c), even though the DNA was assumed to 
be fully bound under these conditions (10 µM DNA, 12.5 µM R100A). This demonstrated 
that the inhibitors prevented substrate conformational rearrangements necessary for 
hydrolysis (Supplementary Figure 15).
N-Hydroxyurea FEN1 inhibitors also target EXO1
FEN1 is the prototypical member of the structure-specific 5ᓉ-nuclease superfamily, also 
comprising exonuclease 1 (EXO1), gap endonuclease 1 (GEN1) and Xeroderma 
Pigmentosum complementation group G protein (XPG).1 Exoribonucleases XRN1 and 2 are 
also suggested members of the superfamily.1 These nucleases all share a similarly-folded 
nuclease domain with similar active site geometry and full conservation of essential catalytic 
residues.1,2 Consequently, it has been hypothesized that the substrate selectivity of these 
proteins stems from strict recognition of their respective DNA substrate structures, followed 
by double nucleotide unpairing to initiate scissile phosphate diester hydrolysis.1
It is known that hFEN1 inhibitors can exhibit limited but manageable promiscuity towards 
XPG.24 However, testing against human EXO1-352Δ (nuclease domain of EXO1)35 
revealed that compounds 1 and 2 both inhibited this target with IC50 values similar to those 
against hFEN1 (Supplementary Figures 5k, 6a,e). Differential scanning fluorimetry 
experiments36 further confirmed binding of both compounds to both proteins in a divalent 
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metal ion-dependent manner (Supplementary Figure 6g,h). In contrast, inhibitor 1 was found 
ineffective against bacteriophage T5 FEN (Supplementary Figures 5l, 6c) and 
Kluyveromyces lactis XRN1 (Supplementary Figure 16), both of which show a high level of 
active site conservation with the mammalian 5ᓉ-nuclease superfamily.1 Similarily, 1 did not 
inhibit the structurally unrelated DNA repair metallonuclease APE1 (Supplementary Figure 
6f).
When hFEN1 acts in vivo it is usually associated with the toroidal clamp PCNA. PCNA 
increases the stability of FEN1–DNA complexes,34 suggesting that association with PCNA 
might allow FEN1 to overcome inhibition. However, when we added hPCNA to hFEN1 
reactions inhibited by 1 or 4, the slow rates of reaction observed did not increase implying 
the FEN1 interaction partner does not dramatically influence the IC50 of either compound 
(Supplementary Figure 6d).
N-Hydroxyurea inhibitors engage with hFEN1 in live cells
On the basis of contrasting inhibition modes, compounds 1 and 4 were selected for 
additional cellular studies. We employed the cellular thermal shift assay technique 
(CETSA)37 to establish whether they interacted with hFEN1 in SW620 colon cancer cells. 
CETSA detects changes in stability of a protein upon engagement with a ligand, like a 
biochemical thermal shift assay, but is performed with whole cells and a target-specific, 
label-free readout of engagement is obtained using a relevant antibody. Compounds 1 and 4 
stabilized hFEN1 (Figure 5a-c and Supplementary Figure 17) with EC50 = 5.1 µM and 6.8 
µM, respectively, in an isothermal concentration–response experiment, representing similar 
EC50s regardless of their differing modes of inhibition. Interestingly, these micromolar-
range values represented a substantial drop-off in observed binding affinity compared with 
observations in prior biochemical assays (IC50 = 46 nM and 17 nM, respectively; Table 1) so 
we undertook a number of experiments to attempt to explain this. Cell permeability in 
MDCK and Caco-2 assays was not an issue (Supplementary Table 4); neither were other 
properties including solubility and chemical stability. The compounds’  affinity for free 
divalent metal ions in solution was insignificant, ruling out metal chelation as an 
explanation. Nonspecific protein binding may have contributed to the discrepancy between 
biochemical and phenotypic potency, although binding to other 5ᓉ-nuclease superfamily 
members represented the most obvious potential for off-target effects. Hence, we attempted 
further CETSA studies with 1 and 4 against hEXO1 but this was concluded to be a non-
viable CETSA target (with only fragments of the protein detected on the blots), perhaps 
reflecting instability of the protein under the assay conditions, or its cellular context as a 
component of multi-protein complexes (which regulate its activity).
hFEN1 inhibition activates the DNA damage checkpoint
High concentrations of compound 1 proved cytotoxic towards SW620 cells with an EC50 of 
11 µM (Figure 5d), but HeLa cells stably expressing hFEN1-shRNA were 70% viable at 20 
µM 1 (Figure 5e; purple curve). Mock-shRNA expressing HeLa cells were only 15% viable 
under the same conditions (Figure 5e; black curve), showing similar susceptibility to 1 as 
untransformed cells. Hence, a lack of hFEN1 conferred resistance to 1, suggesting on-target 
activity as the primary cause of cytotoxicity. SW620 cells also showed increased sensitivity 
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to MMS when co-treated with 1, in a dose-dependent manner (Figure 5f), suggesting the 
compound inhibits the LP-BER function of FEN1 in a cellular context. Enhanced toxicity of 
1 towards HeLa cells expressing Rad54b-shRNA (Figure 5e; green curve) was also observed 
with an EC50 of 6.4 µM compared to 14.9 µM against untransformed cells (Figure 5e,g), 
confirming the synthetic lethal interaction between Fen1 and Rad54b previously 
demonstrated by silencing of the former.18 Inhibitor 4 also proved cytotoxic to HeLa cells 
(EC50 6 µM; Figure 5g), appearing more potent than 1, whose EC50 of approximately 15 µM 
was in line with its toxicity against SW620 cells.
When treated with sub-lethal doses of 1, SW620 cells showed evidence of an induced DNA 
damage response (Figure 5h and Supplementary Figure 18) at concentrations consistent with 
the EC50 for target engagement observed by CETSA. The same compound effected a dose-
dependent increase in ubiquitination of FANCD2, a marker for activation of the Fanconi 
anemia pathway recruited to stabilize stalled replication forks.38–40 At higher doses, 
accumulation of phosphorylated ATM and  ?H2AX was evident, indicating accumulation of 
unrepaired DNA double-strand breaks (DSBs). Cells treated with high concentrations of 1 
also showed evidence of apoptosis, shown by the presence of cleaved PARP (Figure 5h). 
Knockdown of hFEN1 by siRNA activated a similar DNA damage response to treatment 
with 1; these cells accumulated  ?H2AX but otherwise remained viable (Figure 5i and 
Supplementary Figure 19). DNA damage response activation and apoptosis were consistent 
with loss of hFEN1 function, because the consequences of unprocessed Okazaki fragments 
would include stalled or collapsed replication forks, replication errors and double strand 
breaks.
Discussion
N-Hydroxyurea compounds 1, 2 and 4 prevented DNA cleavage with similar efficiency 
(Table 1), reflecting the SAR observed previously for similar-sized compounds24 inasmuch 
as comparable IC50 values were obtained despite notable differences in sidechain size and 
structure. These results were consistent with protein–inhibitor binding mediated primarily 
through interaction with active site Mg2+ ions, and a lack of strong contacts between the 
protein and inhibitor sidechain, as seen in the structure of 1 bound to hFEN1 (Figure 1 and 
Supplementary Table 2). Although the metal-coordinating headgroup clearly provided the 
predominant binding contribution, the elevated KD of 3 suggested interaction of the inhibitor 
sidechain with the protein was nonetheless important for optimal affinity. Further studies 
revealed subtle differences in mode of action on variation of the sidechain structure.
Although the DNA substrate bound in its usual conformation in the presence of compound 
1, hydrolysis was impaired by prevention of double nucleotide unpairing through steric 
blocking of the catalytic metals (Figures 1b-d, 3, 4). These observations were reminiscent of 
the action of the HIV integrase inhibitor raltegravir.41 Raltegravir and functionally related 
compounds bind to active site metal ions of the integrase–DNA complex, similarly 
obstructing access of the reacting phosphodiester bond to the metals. In contrast, compounds 
2 and 4, with altered sidechains, proved mostly competitive in character and primarily acted 
to reduce affinity of the enzyme for its DNA substrate.
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The micromolar EC50s seen in CETSA experiments with 1 and 4 differed markedly from the 
compounds’  nanomolar potency against purified protein – though they were consistent with 
phenotypic potency in DNA damage induction and cytotoxicity assays. A clear explanation 
for this was not found, but the raised cellular EC50s might reflect a high local concentration 
of hFEN1 in the nucleus during S-phase, which could conceivably reach the micromolar 
range. The residence time of compound 1 on hFEN1 proved similar to that of raltegravir on 
its target (4.8 min),42 although this is short compared to the median of 51 min for a 
representative set of marketed drugs,42 so the short residence time of 1 may necessitate a 
high local drug concentration in the vicinity of the target for effective inhibition in cells.
Although hEXO1 is likely inhibited alongside hFEN1, the cellular concentration of hEXO1 
is not expected to be significantly higher, so this seems an unlikely explanation for the raised 
EC50 values. The results with hFEN1-deficient cells (Figure 5e) did suggest some degree of 
target specificity, but previous cellular studies assuming selective inhibition of hFEN1 by the 
N-hydroxyurea series must nonetheless be interpreted with caution based on the likelihood 
of parallel hEXO1 inhibition, since it will not be possible to distinguish between phenotypes 
of hFEN1 and hEXO1 inhibition with this class of compounds. One such published24 
inhibitor, related to 1-4, was employed to help validate a role for hFEN1 in homologous 
recombination (HR),43 demonstrating deficient HR upon treatment. However, hEXO1 is 
essential for competent HR,44–47 and the observed phenotype is explicable by inhibition of 
this enzyme alone. Although a role for hFEN1 in HR is otherwise supported in that study, 
we concluded that the N-hydroxyurea series should not be regarded as exclusive hFEN1 
inhibitors.
The mixed inhibition mode of 1, which in theory permits ‘ dead-end’  complexes of DNA and 
protein to form, did not confer any advantageous inhibition characteristics in cells. 
Unprocessed Okazaki fragments resulting from hFEN1 inhibition might be successfully 
repaired by the cell with apoptosis only resulting when the DNA damage response is 
overwhelmed. Some support for this notion was seen in SW620 cells treated with 1, where 
we observed dose-dependent activation of the Fanconi anemia pathway (Figure 5h). Because 
FANCD2 is recruited to stabilize stalled replication forks and initiate repair,38 treatment 
with 1 evidently did interrupt replication, prompting cells to activate other pathways to 
repair unprocessed Okazaki fragments directly. Failure to achieve this may cause collapse of 
replication forks into DSBs, and at higher doses of compound 1, we did see evidence for 
DSB repair pathway activation. These markers did not accumulate at lower doses, so the 
damage signal may only be obvious when the frequency of DSBs overwhelms the cell’ s 
DNA damage response. Accumulation of cleaved PARP, indicating early apoptosis, also 
suggested cells exposed to 1 were accumulating DNA damage associated with hFEN1 
and/or hEXO1 inhibition and signaling for apoptosis.
Without exposure to inhibitor, both SW620 cells treated with hFEN1-siRNA and HeLa cells 
stably expressing hFEN1-shRNA showed viability indistinguishable from untransformed 
controls yet constitutively initiated a DNA damage response (Figure 5i). The hFEN1-shRNA 
cells showed reduced sensitivity to 1, suggesting a degree of selectivity and on-target activity 
for the compound since the DNA damage reponse remained competent. Our data suggests 
removal of functional hFEN1 alone did not induce toxicity and that damage associated with 
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its loss is successfully repaired until such mechanisms become overwhelmed. This result, 
alongside our other observations in human cells, suggests targeting of hFEN1 in cancer will 
not prove effective as a monotherapy, but could be useful in exploiting synthetic lethal 
vulnerabilities. Synthetic lethal interactions between hFEN1 and Rad54b,18 Cdc416 and 
Mre11a16 are established, and other such interactions with potential clinical relevance are 
proposed.16,38 We confirmed synthetic lethal interaction with Rad54b, previously 
established using hFEN1 knockdown,18 through inhibition of the latter by 1. Thus, hFEN1 
inhibitors might prove beneficial as a component of targeted or personalized therapies, 
provided selectivity over hEXO1 and the other 5ᓉ-endonuclease superfamily members can 
be realized.
Online Methods
Protein Expression and Purification
hFEN1-Wild-type hFEN1 and the mutant hFEN1 protein, R100A, were expressed from 
previously-prepared pET28b vectors containing the appropriate sequences for WT or R100A 
and subsequently purified and stored as described previously.2 The C-terminally truncated 
counterparts of wt-hFEN1 and R100A (i.e. hFEN1-Δ336 and R100A-Δ336 respectively) 
were expressed from previously-prepared pET29b vectors containing the respective 
hFEN1-336 sequence in-frame with a PreScission protease site and (His)6-tag after residue 
336 (removing 44 residues). The proteins were then purified and stored as previously 
described.2 T5FEN protein was expressed and purified as previously described.29
hEXO1-To create a vector for the expression of truncated, wild-type hEXO1-352 bearing an 
in-frame TEV protease site and C-terminal (His)6-tag, primers (5'-
gtctctcccatggggatacagggattgctac-3' and 5'-ggttctccccagctcttgaatgggcaggcatagc-3')—to 
amplify hEXO1-352 DNA bearing leader sequences necessary for ligation independent 
cloning (LIC) with SmaI-digested pMCSG28 vector (DNASU plasmid repository)—were 
utilized according to protocol.48 The DNA sequence encoding hEXO1-352-TEV-(His)6-
Stop was then subcloned from the pMCSG28-hEXO1-352 vector into a pET21a vector using 
the NdeI and NotI restriction sites with appropriate primers (5'-
ggaattccatatggggatacagggattgctac-3' and 5'-ggataagaatgcggccgcttaatgatgatgatggtggtgcc-3'). 
The hEXO1-352-TEV-(His)6 protein was expressed in BL21(DE3)-RIPL E. coli using 
autoinduction media as described. The protein was purified by Co2+-immobilized affinity 
and anion exchange chromatography in a manner analogous to that described previously for 
hFEN1.2 Fractions containing hEXO1-352-TEV-(His)6 were pooled, concentrated using an 
Amicon ultrafiltration device with a 5,000 MWCO membrane and then dialyzed into 2X 2L 
50 mM Tris pH 7.0, 50 mM NaCl, 5 mM DTT, 1 mM EDTA, 5% glycerol containing 1000U 
of TurboTEV (BioVision) to remove the (His)6-tag. The dialysate was treated with 
MagneGST™ glutathione particles to remove the TurboTEV, and then the protein was 
further purified using a Heparin affinity column and a salt gradient from 0 to 1 M NaCl as 
described previously.35 hEXO1-352-containing fractions were pooled, concentrated by 
ultrafiltration as before and then applied to a 16/60 Sephacryl™ S-100 HR (GE Lifesciences) 
column. Fractions containing the protein were concentrated and finally stored at 100 µM at –
20 °C in 50 mM Tris pH 8.0, 50 mM NaCl, 1 mM DTT, 50 µM EDTA, 50% v/v glycerol.
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PCNA-The vector for human PCNA sub-cloned in-frame with a C-terminal-(His)8-tag into 
pET41b using the NdeI and XhoI restricition sites was a kind gift of Professor Binghui Shen 
(Beckman Research Institute, City of Hope). The hPCNA-(His)8 protein was expressed 
overnight at 37 °C in BL21(DE3)-RIPL E. coli using autoinduction media as described.49 
The cells were collected by centrifugation at 6000 g and resuspended in ice-cold PBS buffer. 
The cells were pelleted again and the supernatant was removed. The cell pellet was 
resuspended in Buffer A (25 mM Tris pH=7.4, 0.02% NaN3, 5 mM imidazole, 2 mM  ?-
mercaptoethanol) containing 1M NaCl, 1X EDTA-free protease inhibitor cocktail, and 0.1 
mg/mL lysozyme. After cell lysis by freeze thaw and sonication, Buffer A containing 1% 
Tween-20 (10% of the total volume of the lysate) was added. The lysate was clarified by 
centrifugation at 30,000 g for 30 minutes at 4 °C. The supernatant was then applied to Co2+-
TALON immobilized affinity column and washed with 5 column volumes of Buffer A. The 
column was then washed with 5 CV of Buffer A containing, 200 mM NaCl, and 0.01% 
NP-40. The protein was then eluted in buffer B (25 mM Tris pH=7.4, 0.02% NaN3, 200 mM 
NaC,l 250 mM imidazole, 2 mM  ?-mercaptoethanol, 0.01% NP-40%). The eluate was 
directly applied to two tandem 5 mL Hi-Trap Q columns and further purified as described.50 
Briefly, the fractions containing hPCNA were pooled and dialysed 2 X 2L into Buffer C (25 
mM KPO4 pH=7.0, 0.01% NP-40%, 10% glycerol, 10 mM NaHSO3, 5 mM DTT, 0.02% 
NaN3). The dialysate was passed through a 5 mL Hi-Trap S HP column that was pre-
equilibrated with Buffer C to remove impurities, but hPCNA was found exclusively in the 
flow-through. The flow-through was loaded onto a hydroxylapatite column (BioSepra HA 
Ultrogel, 11 cm by 2.6 cm) and then eluted using a 20-column volume gradient from 0.025 
and 0.5 M KPO4 in Buffer C. The eluate was dialysed 2 X 2Lt into Buffer D (25 mM 
potassium phosphate pH 7.0, 1.5 M (NH4)2SO4, 0.02% NaN3). The dialysate was 
centrifuged at 3,300 g for 10 minutes at 4 °C to remove any precipitate and then loaded onto 
a HiPrep Phenyl-Sepharose FF (high sub) column and eluted using a 20 column volume 
inverse gradient using Buffer D and Buffer E (25 mM potassium phosphate pH 7.0, 10% 
glycverol, 0.02% NaN3). The isolated PCNA was then dialysed into Buffer F (100 mM 
HEPES pH=7.5, 200 mM KCl, 10 mM DTT, 0.1 mM EDTA, 0.04% NaN3), and 
concentrated to provide 200 µM PCNA trimer (i.e. 600 µM monomer) before the addition of 
glycerol to 50% v/v and storage at –20 °C.
KlXRN1-The vector corresponding to residues 1–1245 of Kluyveromyces lactis Xrn1 that 
was subcloned in-frame with a C-terminal hexahistidine tag into pET-26b was a kind gift of 
Professor Liang Tong laboratory (Columbia University). The protein was expressed in 
Rosetta E.coli according to protocol51 and purified as described for hFEN1. Once purified, 
the protein was stored in 20 mM Tris pH = 7.5, 200 mM NaCl, 2 mM DTT and 50% 
glycerol. The purity of all proteins used was assessed by SDS-PAGE (Supplementary Figure 
20).
Crystallisation and Structure Determination—The C-terminally truncated protein 
was crystallized using the hanging drop vapor diffusion method. Briefly, the protein was 
concentrated to approximately 8 mg/mL in a buffer containing 50 mM Tris pH 7.5, 200 mM 
NaCl, 10 mM MgCl2, 1 mM TCEP with 5 mM inhibitor 1 added. The crystallization well 
contained 25% PEG 3350, 0.1 M MOPS pH 7.0, 5% 2-propanol and 2% glycerol. Crystals 
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appeared after 3 days at room temperature. Data were collected at the ERSF synchrotron on 
station ID23 (T = 100 K). Data were processed and scaled using the XDS and SCALA 
software packages.52 The crystals diffracted to 2.8 Å resolution, belong to Space Group P1 
and having unit cell dimensions of a = 43.3Å, b = 50.2 Å, c = 66.9 Å,  挀 = 102.1°,  ?= 
94.0°,  ?= 90.7°. The structure was solved by molecular replacement, model rebuilding was 
conducted using COOT53 and the structure was refined using the BUSTER software.54 The 
final model has good geometry with 92% of residues in the favored region of the 
Ramachandran plot, 7% in the allowed regions and 1% in the disallowed regions as defined 
by PROCHECK.52 At convergence a final crystallographic R-factor of 23.3% was achieved. 
Full data and refinement statistics are shown in Supplementary Table 1 and ligand electron 
density in Supplementary Figure 1.
Isothermal Titration Calorimetry (ITC)—Binding affinities of wt hFEN1, hFEN1-336Δ 
and hFEN1-R100A for compounds 1 and 2 were measured using either a VP-ITC 
microcalorimeter (GE Healthcare) or NANO-ITC (TA Instruments). The appropriate protein 
was exchanged from storage buffer into 100 mM KCl, 1 mM DTT, 50 mM HEPES pH 7.5 
containing 8 mM MgCl2 or 10 mM CaCl2 using a HiPrep 26/10 desalting column at 4 °C. 
Subsequently, the protein was dialyzed overnight at 4 °C against the same buffer 
composition. In all cases, the dialysate was used prepare a solution with final protein 
concentration 18 µM (based on A280 using extinction coefficients calculated using the 
ExPASy ProtParam tool, http://web.expasy.org/protparam/) and final inhibitor concentration 
200 µM, diluted from DMSO stock solution to a final DMSO concentration of 1%. Twenty-
five injections were performed with 180 s spacing time at 25 °C. Titration traces were 
integrated by NITPIC55 and the resultant curves were globally fit by SEDFIT.56 The figures 
were prepared using GUSSI (http://biophysics.swmed.edu/MBR/software.html).
Synthesis and Purification of DNA constructs—The DNA oligonucleotides detailed 
in Supplementary Table 5, including those synthesised with 5ᓉ-fluorescein-CE-
phosphoramidite (6-FAM), internal dSpacer-CE-phosphoramidite (dS) or containing site-
specific 2-aminopurine (2AP) substitutions, were purchased with HPLC purification from 
DNA Technology A/S (Risskov, Denmark). MALDI–TOF spectrometry confirmed 
experimental molecular weights were all within 3 Da of calculated values (data not shown). 
The concentration of individual oligonucleotides was determined by measuring the 
absorbance at 260 nm (20 °C), using an extinction coefficient ( ?260) calculated with 
OligoAnalyzer 3.1 (https://eu.idtdna.com/calc/analyzer). Heteroduplex substrates were 
prepared by heating the appropriate flap (or exo) strand with the complementary template in 
a 10:11 ratio at 95 °C for 5 min in 100 mM KCl, 50 mM HEPES pH 7.5 with subsequent 
cooling to room temperature (Supplementary Table 6 and Supplementary Figure 5).
Steady-state kinetic experiments—Reaction mixtures containing twelve different 
concentrations of FAM-labeled DF1 (Supplementary Figure 5a) substrate were prepared in 
reaction buffer (RB; 55 mM HEPES pH 7.5, 110 mM KCl, 80 mM MgCl2, 0.1 mg/mL 
bovine serum albumin, 1 mM DTT) and incubated at 37 °C for 10 min. Reactions were 
initiated by the addition of hFEN1-336Δ in RB. Reactions were sampled at seven time 
intervals between 2–20 min and quenched with excess EDTA (250 mM) with reaction 
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progress being monitored by dHPLC equipped with a fluorescence detector (Wave® 
fragment analysis system, Transgenomic UK) as described.32 All reactions were 
independently repeated four times. Initial rates (v0, nM min−1) were determined by linear 
regression of plots of the amount of product concentration versus time up to 10% product 
formation. Kinetic parameters kcat and KM were determined by generalized nonlinear least 
squares using a Michaelis–Menten model (Equation 1), from plots of normalized initial rates 
(v0/[E]0, min−1) as a function of substrate concentration. The error distribution was assumed 
to be Gaussian, but to account for the unequal variance with increasing substrate 
concentration the variance was weighted to 1/Y2. All graph fitting and statistical analyses 
were done using GraphPad Prism 6.04 (GraphPad Software, Inc.).
Equation 1
Inhibition Studies—The steady-state kinetic parameters of hFEN1-336Δ with DF1 were 
determined as above at various concentrations of 1, 2 and 4 (0, 5, 10, 50, 100, 500, 1000 
nM) diluted from DMSO stock solutions as required. For each inhibitor concentration, 
reactions were followed in triplicate (each replicate using an independent serial dilution of 
enzyme) at six different concentrations of DF1 (10, 50, 100, 500, 1000, 5000 nM). Each 
experiment was independently conducted twice in triplicate. RB was used with a final 
DMSO concentration of 1% (this DMSO concentration did not affect reaction rates in the 
absence of inhibitor). Reactions were assayed, and normalized initial rates were determined, 
as described for steady-state analyses. Kinetic parameters kcat and KM were determined 
globally for the four simplest types of reversible linear inhibition: uncompetitive (Equation 
2), competitive (Equation 3), non-competitive (Equation 4) and mixed (Equation 5) by non-
linear regression plots of normalized initial rates ( ?o/[E]o, min−1) versus the substrate 
concentration for each concentration of inhibitor. The same weighting as above (1/Y2) was 
applied in each case. In addition to the goodness of fit of these calculated slopes to the raw 
normalized initial rates, statistical analyses were done using GraphPad Prism. Akaike 
information criteria (AIC) was employed as a statistical test to aid model selection (e.g. non-
competitive versus competitive). Unless the more complex model gave a difference in AIC 
of more than –6 (95% probability), the less complex model was preferred as the appropriate 
one. This type of analysis penalizes the more parameterized model unless the sum-of-
squares is significantly reduced. As an additional check, the residuals from both the non-
competitive and mixed inhibition models were inspected. IC50 values for inhibition of 
hFEN1-336Δ by compounds 1, 2 and 4 (reported in Table 1) were derived from data 
obtained at 100 nM substrate DF1 and the same concentrations of inhibitor as above, using 
nonlinear regression in GraphPad Prism.
Equation 2
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Equation 3
Equation 4
Equation 5
The rates of reaction of hFEN1-, hFEN1–PCNA-, hEXO1- and T5FEN-catalysed reactions 
of SF, DF4, EO and pY7 (Supplementary Tables 5,6 and Supplementary Figure 5h,i), 
respectively, were also determined at varying concentrations of compounds 1 and 4 
(hFEN1–PCNA), 1 and 2 (hEXO1) or 1 only (T5FEN) in an analogous fashion at fixed 
concentrations of substrate as detailed in Supplementary Figure 6b–e.
RNA and DNA oligonucleotides used in XRN1 assays were ordered purified using reverse-
phase HPLC and synthesised by DNA Technology (Risskov, Denmark), using standard 
phosphoramidites. Reactions were performed as described,51 but were monitored by 
denaturing PAGE using a Chemidoc system (Bio-Rad) to visualize the FAM and TAMRA 
labelled oligos (Supplementary Figure 16).
Human APE1 was purchased from Sino Biologicals via Life Technologies. APE1 was 
assayed with the AP1 substrate57 in 50 mM HEPES-KOH pH 7.5, 25 mM KCl, 5 mM 
MgCl2 and 0.1 mg/mL BSA. The reaction was monitored by dHPLC in a manner analogus 
to FEN1.
Determination of kSTmax of hFEN1, hFEN1-336∆ and hFEN1-R100A in the 
presence and absence of inhibitors—Maximal single turnover rates of reaction were 
determined using rapid quench apparatus, or manual sampling where appropriate, in 
triplicate (technical replicates) at 37 °C as described.32 To initiate reaction, enzyme at a 
final concentration of at least 10 × Kd of the substrate (DF1; Supplementary Tables 56 and 
Supplementary Figure 5a) in RB was added to an equal volume of substrate in the same 
buffer. To determine kSTmax in the presence of the inhibitor 1 or 2, reaction mixtures were 
prepared as above but containing 100 µM (1% DMSO) of either inhibitor. Samples were 
quenched (1.5 M NaOH, 80 mM EDTA) over a range of different time intervals and reaction 
progress monitored as above.32 The first-order rate constant (kSTmax) of reaction was 
determined by plotting the appearance of product against time (Pt) and applying nonlinear 
regression to Equation 6, where Pᙜ is the amount of product at endpoint.
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Equation 6
Fluorescence Anisotropy—Dissociation constants for free enzyme and the enzyme–
inhibitor complex with the DNA substrate (DF1; Supplementary Tables 5,6 and 
Supplementary Figure 5a) were measured under equilibrium conditions by fluorescence 
anisotropy using a Horiba Jobin Yvon FluoroMax-3® spectrofluorometer with automatic 
polarizers. The excitation wavelength was 490 nm (slit width 5 nm) with emission detected 
at 510 nm (slit width 5 nm). Samples contained 10 mM CaCl2 or 2 mM EDTA (or when 
inhibitors were present 8 mM MgCl2) and 10 nM DF1, 110 mM KCl, 55 mM HEPES pH 
7.5, 0.1 mg/mL bovine serum albumin, 1 mM DTT and 1% DMSO. Inhibitors 1 and 2 were 
added at 100 µM as appropriate. This solution containing substrate was incubated at 37 °C 
for a minimum of 10 min before the first measurement at 0 nM protein with subsequent 
readings taken on the cumulative addition of enzyme in a matched buffer, with corrections 
made for dilution. Data were modeled by nonlinear least squares regression in KaleidaGraph 
4.0 using Equation 7, where r is the measured anisotropy at a particular total concentration 
of enzyme ([E]) and fluorescent substrate ([S]), with rmin giving the minimum anisotropy, of 
free DNA, and rmax the maximum anisotropy, the anisotropy of the saturated substrate.
Equation 7
The equilibrium dissociation constant Kd(binding) is extracted from this analysis. Each 
measurement was independently repeated in triplicate (Supplementary Figure 10), and 
samples were taken after completion of the titration and analyzed by dHPLC to determine 
the amount of product produced (Supplementary Figure 11a).
Fluorescence Anisotropy Competition Experiments—Samples were prepared and 
anisotropy readings taken as described for the protein–DNA equilibrium binding 
measurements above. Enzyme was added cumulatively up to ~ 80% saturation of the 
substrate (DF1; Supplementary Tables 5,6 and Supplementary Figure 5a). At this point 
unlabeled DNA in the same buffer (DF2; Supplementary Table 5,6 and Supplementary 
Figure 5b) was added in a stepwise manner with readings taken after each addition of the 
competitor until the anisotropy value reached that of oligonucleotide in the absence of any 
protein (Supplementary Figure 11h).
Fluorescence Resonance Energy Transfer (FRET)—FRET energy transfer 
efficiencies (E) were determined using the (ratio)A method58 by measuring the enhanced 
acceptor fluorescence. The steady state fluorescent spectra of 10 nM non-labeled 
trimolecular, donor-only labeled and doubly-labeled DNA substrates (Supplementary Figure 
5c,d,f) were recorded using a Horiba Jobin Yvon FluoroMax-3® fluorometer and normalized 
for lamp and wavelength variations. For direct excitation of the donor (fluorescein, DOL) or 
acceptor (rhodamine, AOL; Supplementary Figure 5e), the sample was excited at 490 nm or 
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560 nm (2 nm slit width) and the emission signal collected form 515–650 nm or 575–650 
nm (5 nm slit width). Emission spectra were corrected for buffer and enzyme background 
signal by subtracting the signal form the non-labeled (NL) DNA sample. In addition to 10 
nM of the appropriate DNA construct samples contained 10 mM CaCl2 or when inhibitor 
was present 8 mM MgCl2 or 2 mM EDTA and 110 mM KCl, 55 mM HEPES pH 7.5, 0.1 
mg/mL bovine serum albumin, 1 mM DTT, 1% DMSO and 100 µM inhibitor 1or 2 as 
appropriate. The first measurement was taken prior to the addition of protein (either hFEN1-
WT or hFEN1-R100A) with subsequent readings taken on the cumulative addition of 
enzyme, with corrections made for dilution. Transfer efficiencies (E) were determined 
according to Equation 8, where FDA and FD represent the fluorescent signal of the doubly-
labeled DNA (DAL) and donor-only-labeled DNA (DOL) at the given wavelengths, 
respectively;  ?D and  ?A are the molar absorption coefficients of donor and acceptor at the 
given wavelengths; and  ?D(490)/ ?A(560) and  ?A(490)/ ?A(560) are determined from the 
absorbance spectra of doubly-labeled molecules (DAL) and the excitation spectra of singly 
rhodamine-only-labeled molecules (AOL). Energy transfer efficiency (E) was fit by non-
linear regression to Equation 9, where Emin and Emax are the minima and maxima of energy 
transfers, [S] is the substrate concentration, [P] is the protein concentration and KD is the 
bending equilibrium dissociation constant of the protein substrate [PS] complex.
Equation 8
Equation 9
2-Aminopurine Exciton-Coupled Circular Dichroism (ECCD) Spectroscopy—
Spectra were recorded of samples containing 10 µM DF3 (Supplementary Figure 5g), 110 
mM KCl, 55 mM HEPES pH 7.5, 1 mM DTT and either 10 mM CaCl2; 10 mM CaCl2 + 25 
mM EDTA; 8 mM MgCl2 + 100 µM compound 1 or 2; or 8 mM MgCl2 + 100 µM 
compound 1 or 2 + 25 mM EDTA; and, where appropriate, 12.5 µM protein, using a JASCO 
J-810 CD spectrophotometer (300–480 nm) at 20 °C as described.28 In samples containing 
either inhibitor 1 or 2, the enzyme was pre-incubated with the inhibitor before addition of 
the substrate. The CD spectra were plotted as Δ ? per mol of 2AP residue versus wavelength. 
Each measurement was independently repeated (typically in triplicate) and gave similar 
results. After measurements were recorded aliquots were taken and the amount of product 
produced was checked by dHPLC (Supplementary Figure 12b).
Differential Scanning Fluorimetry (DSF)—The stability of purified hFEN1 and 
hEXO1-352 with and without available Mg2+ was assessed as a function of inhibitor 
concentration by DSF36 using the fluorescent probe SYPRO® Orange (Sigma–Aldrich). 
Final volumes of 20 µL containing 2.5 µM hFEN1 or hEXO1-352 in 50 mM HEPES–KOH 
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pH 7.5, 100 mM KCl, 8 mM MgCl2, 1× SYPRO® Orange with either 25 mM EDTA or 25 
mM NaCl and various concentrations of compound 1 or 2 (0, 1, 2, 4, 6, 8, 10, 20, 40, 60, 80, 
100 µM) were mixed in white 96-well PCR-plates (Starlab) and sealed with StarSeal 
Advanced Polyolefin Film (Starlab). The plates were inserted into an Agilent MX3005P 
QPCR instrument for thermal denaturation. The emission at 610 nm (excitation 492 nm) 
from each well was recorded from 25 to 95 °C at a scan rate of 1 °C/min with a filter set 
gain multiplier of ×4. Analysis of the resulting thermal denaturation curves was 
accomplished using the DSF Analysis Excel36 script as described (ftp://
ftp.sgc.ox.ac.uk/pub/biophysics) in combination with GraphPad Prism 6.04, which provided 
the nonlinear regression function with the Boltzman equation (Equation 10).
Equation 10
Cellular Thermal Shift Assay (CETSA)
CETSA was performed as described37 by first establishing melt curves and ligand-induced 
shifts followed by testing of the compounds with increasing concentrations of 1 or 4 at a 
single temperature to establish the CETSA EC50 of target engagement. Target engagement 
was determined by isothermal concentration–response (IsoT C–R) stabilization curves for 
compound 1 and 4 on hFEN1 in treated intact cells. Western blots were performed using an 
iBlot2 device (Life Technologies) on nitrocellulose membranes. Transfer was set to 8 
minutes at 25 V. Blocking and dilution of antibodies were performed in 5% non-fat milk in 
Tris Buffered Saline–Tween (TBST). A commercially available primary antibody against 
hFEN1 (ab109132, Abcam) was diluted at 1:5000 and incubated at 4 °C overnight. Specific 
hFEN1 bands were then detected using the horseradish peroxidase (HRP) conjugated 
secondary antibody sc-2374 (Santa Cruz Biotechnology) together with Clarity Western ECL 
substrate (BioRad).
Melt and shift curves (Figure 5a,b) for FEN1 in intact SW-620 cells were determined by 
washing cells with HBSS followed by trypsinization using TrypLE (Gibco) and pelleting by 
centrifugation. The pellet was washed with HBSS, pelleted and re-suspended in HBSS to a 
cell density of 20 million cells/mL. Compound incubation was performed during 60 minutes 
at 37 °C at 100 µM final concentration, whereas 0.2% DMSO was used as negative control. 
The samples were gently mixed every 10 min. Cell viability was measured before and after 
compound incubation. The treated cells were divided into 50 µL aliquots and subjected to a 
12-step heat challenge between 37 and 70 °C for 3 min, followed by immediate cell lysis by 
3 rounds of freeze–thawing. Precipitated protein was pelleted by centrifugation at 20,000 g 
for 20 min, then 30 µL of the supernatant was mixed with 15 µL gel loading buffer 
(NuPAGE LDS sample buffer, Life Technologies) and 10 µL/lane of the mixture was loaded 
to a gel. Protein amounts were detected using Western blot techniques as described above.
Isothermal concentration response curves (Figure 5c) were determined with intact SW-620 
cells treated as above, but at a final concentration of 40 million cells/mL. The cell 
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suspension was divided into 30 µL aliquots and an equal volume of HBSS containing 2× the 
intended compound concentration was added, resulting in a final cell concentration of 20 
million cells/mL at the correct concentration. A 7-step dilution concentration response series 
of the ligands in 0.2% DMSO was applied together with 0.2% DMSO as control. The log10 
dilution series ranged from 100 pM to 100 µM. An additional 7-step series was applied, 
ranging from 100 nM to 300 µM. The cells were incubated with ligand at 37 °C for 60 min, 
with gentle mixing every 10 min. The aliquots were heated to a single specific temperature, 
50 °C, as determined from the previously established FEN1 melt and shift curves, for 3 min, 
and lysed by 3 cycles of freeze–thawing. Precipitated protein and cellular debris were 
pelleted by centrifugation at 20.000 g for 20 min then 40 µL of the supernatant was mixed 
with 20 µL LDS sample buffer. Protein amounts were detected after loading 10 µL/lane of 
the supernatant/LDS mixture per on a gel using standard Western blot techniques.
The Western blot intensities were obtained by measuring the chemiluminescence counts per 
mm2 (I = count/mm2). The obtained intensities were plotted in GraphPad Prism for melt 
curves, with the luminescence count normalized to the control count at 37 °C. The IsoT C–R 
data was analyzed and normalized to the maximum compound concentration. The 
normalized intensities were plotted and analyzed using GraphPad Prism. Data points are 
shown as mean values with error bars indicating the standard error of the mean. 
Concentration–response curves were fitted using the modified logistic Hill equation 
algorithm included in the GraphPad Prism software. The obtained CETSA™ EC50 
concentration response values represent the half maximal concentration of the ligands for 
stabilizing hFEN1 at 50 °C. The quoted EC50 with 95% confidence intervals is therefore a 
relative measure of target engagement of compound available for interaction with FEN1 in 
intact SW-620 cells.
Cytotoxicity Assay—SW620 cells were obtained from ATCC and HeLa SilenciX cell 
lines stably expressing shRNA against Fen1, Rad54b or a non-targeting control were 
obtained from Tebu Biosciences. Cell-line identity was confimed by short tandem repeat 
fingerprinting prior to banking and cells are routinely tested for mycoplasma contamination. 
SilenciX gene knockdown was confirmed by quantitative PCR. Exponentially growing cells 
were split into 6-well plates at an appropriate density in Dulbecco’ s Modified Eagle’ s 
Medium (DMEM) supplemented with 2 mM L-glutamine and 10% foetal calf serum (FCS) 
and incubated for 24 h to allow cells to adhere. Cells were treated with compound 1 or 4 
(diluted from DMSO stock solution) at the concentration stated. For the MMS sensitivity 
assay, cells were pre-treated with 100 µM MMS in DMEM for 2 h before replacing the 
media with DMEM containing the stated concentration of 1 or 4. For siRNA survival assays, 
Fen1 knockdown was achieved by treating with targeting and non-targeting siRNA pools 
(Dharmacon) for 24 h using RNAiMAX lipofectamine transfection reagent (Life 
Technologies) before cells were allowed to recover in fresh media. In all cases, plates were 
incubated for 10–14 days to allow for colony formation. Colonies were stained with crystal 
violet and colony frequencies determined using the GelCount automated system (Oxford 
Optronix). Survival is expressed as a percentage of a mock-treated control. Knockdown of 
Fen1 by siRNA was confirmed by Western blot.
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DNA Damage Induction Assay—Exponentially growing SW620 cells were seeded in 6-
well plates and incubated for 4 days with compound 1 at the stated dose. Cells were 
subsequently washed, trypsinized and lysed in Cell Panel Lysis Buffer (5 mM Tris-HCl, 3 
mM EDTA, 3 mM EGTA, 50 mM NaF, 2 mM sodium orthovanadate, 0.27 M sucrose, 10 
mM  ?-glycerophosphate, 5 mM sodium pyrophosphate, and 0.5% Triton X-100) 
supplemented with complete protease and phosSTOP phosphotase inhibitors (both Roche). 
Proteins were separated by gel electrophoresis and transferred to nitrocellulose membrane 
by Western blot. Membranes were probed, at a concentration of 1:1000 unless stated 
otherwise, for cleaved PARP (#9541, Cell Signaling Technology),  ?H2AX (#2577, Cell 
Signaling Technology; 1:500), GAPDH (#3683, Cell Signaling Technology; 1:5000), FEN1 
(ab109132, Abcam), phospho-ATM (Ser1981) (ab81292, Abcam), PARP (51-6639GR, BD 
Biosciences), ATM (sc-23921, Santa Cruz Biotechnology) and FANCD2 (sc-20022, Santa 
Cruz Biotechnology).
Accession Codes—The PDB accession code for the X-ray crystal structure of compound 
1 bound to human FEN1, as detailed above, is 5FV7.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Compounds used in this study and crystal structure of hFEN1-336∆ in complex with 
compound 1.
(a) Schematic illustration of compounds 1–4 that are inhibitors of hFEN1 phosphate diester 
hydrolysis. (b) Structure of hFEN1-336Δ nuclease active site (PDB ID 5FV7) showing the 
seven highly-conserved acidic residues (grey and red spheres represent carbonyl carbon and 
oxygen atoms, respectively), the two bound magnesium ions (pink spheres), and compound 
1. (c) Schematic representation of the metal-coordination spheres of the two active site 
magnesium ions with distances reported in Ångstrom. (d) Structure of hFEN1-336Δ in 
complex with product DNA (PDB ID 3Q8K) superimposed with the hFEN1-336Δ in 
complex with compound 1 (protein not shown) to show that the inhibitor and terminal 
nucleotide of the product DNA interact with the divalent magnesium ions and share same 
pocket created by the protein. Metals are shown as pink spheres, terminal 5ᓉnucleotide (–1) 
highlighted in cyan box, penultimate nucleotide of the product DNA (–2) highlighted in the 
pink box, and compound 1 highlighted in the green box.
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Figure 2. Differences in inhibition characteristics of the compounds.
(a) hFEN1-catalyzed reaction schematic showing double nucleotide unpairing at positions 
+1 and −1 (numbering relative to scissile phosphate). (b,c) Reaction schemes of mixed 
inhibition (b) and competitive inhibition (c) models. In each case, E, S, I and P represent 
enzyme, substrate, inhibitor and product, respectively. Kic is the dissociation constant of I 
from free enzyme (competitive with substrate) and Kiu is the dissociation constant of I from 
ES complex (uncompetitive). (d–f) Nonlinear regression plots of normalized initial rates of 
reaction vs. substrate concentration (open diamonds) for substrate DF1 at varying 
concentrations of compounds 1 (d; inset shows equation for mixed inhibition model), 2 (e; 
inset shows legend correlating color/symbol to inhibitor concentration) and 4 (f; inset shows 
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equation for competitive inhibition model). Error bars represent standard errors from global 
fitting of combined data from two triplicate experiments (fits to alternative models are 
shown in Supplementary Figures S7–S9).
Exell et al. Page 25
Nat Chem Biol. Author manuscript; available in PMC 2017 March 23.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 3. Effect of inhibitors on substrate binding assessed by fluorescence anisotropy (FA) and 
FRET.
(a) Typical FA titration data for hFEN1-R100A binding DF1 in the presence of 10 mM Ca2+ 
(magenta, open triangles), 8 mM Mg2+ plus 100 µM compound 1 (blue, open circles) or 8 
mM Mg2+ with 100 µM compound 2 (green, open squares); three independent titrations 
were carried out for all FA binding experiments. (b) Representative curves of typical 
normalized FRET binding data for DF1 and hFEN1-R100A. Experiments were conducted in 
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triplicate, but only one data set and curve is shown here for each titration. Colours and 
symbols for each of the three plots are the same as in panel (a).
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Figure 4. N-Hydroxyurea inhibitors prevent FEN1 reaction by blocking substrate unpairing.
CD spectra recorded at pH 7.5 and 20 °C of (a) tandem 2-aminopurine containing substrate 
DF3 (illustrated schematically as inset, and Supplementary Figure 5g) alone in the presence 
of 10 mM Ca2+ (blue) or 25 mM EDTA (grey) and the same substrate bound to hFEN1-
R100A in the presence of 10 mM Ca2+ (magenta) or 25 mM EDTA (green); (b) DF3 bound 
to hFEN1-R100A in the presence of Mg2+ plus excess compound 1 (cyan) or EDTA plus 
excess compound 1 (red); (c) DF3 bound to hFEN1-R100A with excess compound 2 in the 
presence of Mg2+ (orange) or EDTA (purple). Full DNA sequences are shown in 
Supplementary Tables 5,6 and Supplementary Figure 5g. Plots in panels a–c are 
representative of experiments repeated independently three times.
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Figure 5. Cellular engagement and activity of hFEN1 inhibitors 1 and 4.
(a) Representative data of Western blot intensities from a melt curve for compound 1 ((+) 
indicates treated sample, (−) indicates control sample). (b) Melt and shift curve of FEN1 in 
intact SW620 cells with 100 µM 1 (purple), 4 (orange) and DMSO (control, black). (c) Ratio 
of hFEN1 protein isothermal shifts in cells with respect to concentration of compounds 1 
(purple) or 4 (orange) after exposure of cells to 50 °C to indicate magnitude of target 
engagement of FEN1 in intact treated SW620 cells. (d) Dose-dependent sensitivity of 
SW620 cells to compound 1. (e) Sensitivity of HeLa cells stably expressing Fen1 (orange), 
Rad54b (green) or non-targeting (black) shRNA to compound 1. (f) MMS sensitivity of 
SW620 cells treated with continuous dose of 10 µM compound 1 (purple) or DMSO 
(control, black). (g) Dose-dependent sensitivity of HeLa cells to compounds 1 and 4. (h) 
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Typical Western blots showing 1 induces a DNA damage response in a dose-dependent 
manner. (i) SW620 cells are insensitive to deletion of FEN1 by siRNA, but accumulate DNA 
damage. Panels (b) and (c) show data from three independent triplicate experiments, fitted 
globally (i.e. N = 3, n = 9) with standard error. Panels (d)–(g) and (i) show the mean of three 
independent experiments ± standard error. Full images of cut gels used to prepare panels (h) 
and (i) are included in Supplementary Figures 18 and 19, respectively.
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Table 1
Kinetic parameters in absence and presence of inhibitors.
Enzyme Inhibitor IC50, nM§ kcat, min-1 KM, nM Kic, nM Kiu, nM kSTmax, min–1 t1/2, min ∆AICc
hFEN1 None n.a. 165±9 20±3 n.a. n.a. 916±49 7.57×10−4 n.a.
hFEN1 1 n.d. n.d. n.d. n.d. n.d. 0.48±0.04 1.43 n.a.
hFEN1 2 n.d. n.d. n.d. n.d. n.d. 1.52±0.09 0.46 n.a.
hFEN1-336Δ None n.a. 160±10 151±16 n.a. n.a. 755±35 8.94±10−4 n.a.
hFEN1-336Δ 1 46.4±4.8 140±9 297±31 48±5 117±27 n.d. n.d. 24.76*
hFEN1-336Δ 2 30.0±6.0 182±13 422±50 17±2 306±125 n.d. n.d. 10.21¶
hFEN1-R100A None n.a. n.d. n.d. n.d. n.d. 0.087±0.003 7.94 n.a.
hFEN1-R100A 1 n.d. n.d. n.d. n.d. n.d. ~4×10−4 ≤1750 n.a.
hFEN1-R100A 2 n.d. n.d. n.d. n.d. n.d. ~2×10−3 ≤360 n.a.
hFEN1-336Δ 4 16.9±1.2 194.5±11 630.8±53 26±2 n.a. n.d. n.d. Amb.
§
IC50 values derived from rates at substrate concentration close to KM (100 nM). kSTmax is maximal reaction rate under single turnover 
conditions, used to calculate the substrate half-life (t1/2). ΔAICc is the difference between second order (corrected) Akaike Information Criteria 
values between models; if ≥6, the likelihood the incorrect model was selected is P < 0.0001. ΔAICc for 1* and 2¶ compares non-competitive with 
mixed-inhibition models and competitive with mixed-inhibition models, respectively. Mixed-inhibition is preferred for both. For 4, competitive 
inhibition was the only model whose fit was not ambiguous (Amb.).
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